R R

What Is Olaparib?

Olaparib is a prescription targeted cancer medication marketed under the name Lynparza. It belongs to a class of medicines called poly (ADP-ribose) polymerase inhibitors, or PARP inhibitors. Olaparib treats selected ovarian, breast, pancreatic, and prostate cancers, depending on their genetic characteristics, disease stage, and previous treatments. Some patients receive it as maintenance therapy following chemotherapy, while others receive it to treat active cancer. Olaparib is taken orally and requires monitoring by an oncology specialist.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Olaparib?

Olaparib is a prescription targeted cancer medication marketed under the name Lynparza. It belongs to a class of medicines called poly (ADP-ribose) polymerase inhibitors, or PARP inhibitors. Olaparib treats selected ovarian, breast, pancreatic, and prostate cancers, depending on their genetic characteristics, disease stage, and previous treatments. Some patients receive it as maintenance therapy following chemotherapy, while others receive it to treat active cancer. Olaparib is taken orally and requires monitoring by an oncology specialist.

read more about olaparib ...

Copy this HTML:

Copy HTML Copied!

How Does Olaparib Work?

Olaparib blocks PARP enzymes, particularly PARP1 and PARP2, which help repair damaged DNA. Cancer cells with certain defects in DNA repair pathways, including BRCA1 or BRCA2 mutations, can be especially vulnerable to PARP inhibition. Blocking these enzymes can cause DNA damage to accumulate, interfering with cancer cell survival. Olaparib can also trap PARP proteins on damaged DNA, contributing to its antitumor activity. Its effects depend partly on the molecular characteristics of the cancer being treated.

What Types of Cancer Does Olaparib Treat?

Olaparib is approved for selected forms of ovarian cancer, including certain maintenance treatment settings after platinum-based chemotherapy. It also treats specific HER2-negative breast cancers with inherited BRCA mutations, metastatic pancreatic cancer with inherited BRCA mutations in a maintenance setting, and selected metastatic castration-resistant prostate cancers with relevant DNA repair gene alterations. Some indications involve combination treatment with bevacizumab or abiraterone and corticosteroids. Genetic testing and previous treatment history help determine eligibility.

How Should Olaparib Be Taken?

The usual recommended olaparib tablet dose is 300 mg orally twice daily, with or without food. Tablets should be swallowed whole rather than crushed, chewed, dissolved, or divided. Dose reductions can be necessary for adverse reactions, moderate kidney impairment, or interactions with certain medications. Patients should avoid grapefruit and Seville oranges because they can affect drug exposure. Missed doses should be skipped rather than doubled. Olaparib tablets and older capsule formulations are not interchangeable on a milligram-for-milligram basis.

What Are the Side Effects and Warnings of Olaparib?

Common adverse effects include nausea, fatigue, anemia, vomiting, diarrhea, reduced appetite, and changes in blood counts. Serious risks include myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, and blood clots in certain treatment settings. Olaparib can harm an unborn baby and requires pregnancy prevention precautions. Clinicians monitor blood counts before and during treatment. Persistent breathlessness, fever, unusual bruising, or severe weakness should be reported promptly. Medication interactions can also increase olaparib exposure and toxicity.

Common Questions About Olaparib

Is olaparib a chemotherapy drug?

Olaparib is a targeted cancer medication classified as a PARP inhibitor. It works differently from traditional cytotoxic chemotherapy, although it can be prescribed following or alongside other cancer treatments.

Is olaparib the same as Lynparza?

Yes. Lynparza is the brand name for olaparib, a prescription PARP inhibitor used for selected cancers.

Does olaparib treat BRCA-mutated cancers?

Yes. Several approved olaparib indications involve cancers with BRCA1 or BRCA2 mutations. Other indications involve specific homologous recombination repair abnormalities.

Can olaparib cause anemia?

Yes. Anemia and other blood cell abnormalities are recognized adverse effects. Blood counts are monitored before treatment and regularly afterward.

References

DailyMed - LYNPARZA (olaparib) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa. Date Accessed October 22, 2026.

Olaparib. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547873/. Date Accessed October 22, 2026.

Olaparib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a614060.html. Date Accessed October 22, 2026.

Olaparib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/olaparib. Date Accessed October 22, 2026.

Olaparib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib. Date Accessed October 22, 2026.